Devices & Diagnostics FDA device approval imminent? Impressive CoreValve data allows Medtronic to skip advisory panel By Lindsey Alexander
Devices & Diagnostics Medtronic’s CoreValve demonstrates quality-of-life improvements By Arundhati Parmar
Devices & Diagnostics Medtronic not barred from making CoreValve device, judge decides By MassDevice Staff
Devices & Diagnostics Medtronic CEO expects to submit renal denervation data to FDA this year, overcoming previous failures By Arundhati Parmar
Devices & Diagnostics Israeli medtech firm raised $15M to treat heart-failure patients with catheter-based therapy By Karen Young
Devices & Diagnostics The cost of Medtronic’s battle with Edwards Lifesciences over TAVI: $245M, so far By Arundhati Parmar
Devices & Diagnostics California startup developing catheter-based technology for mitral valve repair lands $32.5M By Arundhati Parmar
Devices & Diagnostics Are transcatheter aortic valve implantations overused? Edwards Lifesciences disagrees By Arundhati Parmar
Devices & Diagnostics Edwards Lifesciences’ transcatheter heart valve sales jump 71 percent year over year By Arundhati Parmar
Devices & Diagnostics TAVR will drive U.S. heart valve market to reach $1.5 billion in 2016 By Arundhati Parmar
Devices & Diagnostics FDA panel recommends Edwards’ heart valves for high-risk patients By Arundhati Parmar
Devices & Diagnostics Why a Medtronic executive wants rival Edwards Lifesciences to succeed By Arundhati Parmar
Devices & Diagnostics What the TAVI trials’ stroke data means for Medtronic and Edwards By Arundhati Parmar